TRiPOD

 

Treg Repertoire in Physiology or Diseases

Rationale

The TriPoD project is based on 3 well-supported assertions:

  • Regulatory T cells (Tregs) have huge therapeutic potential
  • Deep understanding of the Treg repertoire is key to exploiting this therapeutic potential
  • Deep sequencing technologies required for this purpose have come of age

 

Objectives

  • Identify the repertoire of TCRs specific for insulin and myelin, from mouse and human Tregs.
  • Study the above identified TCRs within the Treg/Teff repertoires during thymocyte differentiation and in the periphery; according to age and sex and during IL-2 treatment, in normal and NOD mice and during EAE.
  • Study the above identified TCRs within the Treg/Teff repertoires during thymocyte differentiation, in cord blood, and in the periphery according to age and sex, in HLA DR1 and DR3 selected normal individuals, and T1D and MS patients, including during IL-2 treatment.
  • Discover TCRs biomarkers of T1D and MS prediction/progression.
  • Generate and test “super-active” antigen-specific Tregs in T1D and MS models.
  • Set up a high-throughput assay for the evaluation of the entire Treg TCR/cognate antigen repertoire.